clinical trial · NCT06494761
A Study in Healthy Men to Test Whether Zongertinib Affects How 3 Other Medicines (Midazolam, Omeprazole, and Repaglinide) Are Taken up and Processed by the Body
Boehringer Ingelheim·phase1·completed·n = 16
Healthyzongertinibmidazolamomeprazolerepaglinide
brief summary
The main objective of this trial is to assess the effect of multiple oral doses of zongertinib on the pharmacokinetics of midazolam, omeprazole and repaglinide.
started
Jul 30, 2024
primary completion
Oct 16, 2024
completion
Oct 16, 2024
last updated
Dec 2, 2025
official title
The Effect of Multiple Doses of Zongertinib on the Single-dose Pharmacokinetics of Midazolam, Omeprazole and Repaglinide in Healthy Male Subjects (an Open-label, 2-period, Fixed-sequence Trial)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol